Singapore markets closed

T2 Biosystems, Inc. (TTOO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0500+0.1900 (+6.64%)
At close: 04:00PM EDT
3.0800 +0.03 (+0.98%)
Pre-market: 06:12AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.8600
Open2.8600
Bid2.9900 x 100
Ask3.1200 x 400
Day's range2.8100 - 3.2200
52-week range2.7000 - 70.0000
Volume267,379
Avg. volume286,937
Market cap15.044M
Beta (5Y monthly)0.13
PE ratio (TTM)N/A
EPS (TTM)-35.6200
Earnings date21 May 2024 - 28 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.00
  • GlobeNewswire

    T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

    Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates. Recent Highlights Announced plans to commercialize the T2Lyme Panel in the third quarter of 2024 as a laboratory developed tes

  • GlobeNewswire

    T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates

    LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by

  • GlobeNewswire

    T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

    Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genesLEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clin